(Reuters) – Britain’s drug regulator on Thursday approved GSK and Vir Biotechnology’s antibody based COVID-19 treatment, Xevudy, for people with mild-to-moderate COVID-19 who are at high risk of developing severe disease.
The approval comes as GSK separately announced the treatment has shown to work against the Omicron variant.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)
